Navigation Links
Regeneron Joins Human Vaccines Project to Improve Global Disease Prevention and Treatment
Date:2/10/2016

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined the Human Vaccines Project, a public-private partnership to help discover and develop new vaccines and immunotherapies for infectious diseases and cancer.

The Human Vaccines Project brings together leading pharmaceutical and biotechnology companies, academic institutions, and government and non-profit health organizations to accelerate the development of new and improved vaccines and immunotherapies. Under the collaboration, Regeneron will provide scientific guidance and financial support for research designed to better understand the human immune response to licensed and experimental vaccines.

“At Regeneron, we are focused on turning scientific and technological expertise into improved medical outcomes,” said Neil Stahl, Ph.D., Executive Vice President of Research and Development at Regeneron. “Regeneron’s unique VelociSuite® technologies may enable more predictive testing of vaccines and other immunotherapies in fully-humanized and validated in vivo models, offering the potential for more precise and efficient therapeutic development. We look forward to collaborating with other world-class scientists as part of this consortium.”

The Human Vaccines Project’s scientific approach includes two initiatives:

  •     The Human Immunome program is a seven-to-10-year effort to sequence the adaptive components of the immune system across diverse populations. This approach could provide an indispensable "parts list" that would allow for the design of highly targeted new vaccines and therapies.
  •     The Rules of Immunogenicity program will conduct a large number of small, iterative clinical trials investigating immune responses to try to solve key problems that impede vaccine/immunotherapy development.

“As a long-time leader in biotechnology, Regeneron brings a science-based approach and important translational medicine capabilities to our collaboration,” said Wayne C. Koff, Ph.D., Founder of the Human Vaccines Project and Chief Scientific Officer of the International AIDS Vaccine Initiative (IAVI), which incubated the Human Vaccines Project. “Given recent technological developments in genomics, bioinformatics and systems biology, we are confident that the time is right to consolidate our partners’ knowledge in an innovative global consortium whose goal is to advance a new generation of vaccines and immunotherapies that could prevent or control major global diseases."

About the Human Vaccines Project
The Human Vaccines Project is a non-profit public-private partnership with the mission to accelerate the development of vaccines and immunotherapies against major infectious diseases and cancers by decoding the human immune system. The Project, incubated initially at the International AIDS Vaccine Initiative (IAVI), is supported by the Robert Wood Johnson Foundation, Regeneron, GSK, Aeras, MedImmune, Sanofi Pasteur, Crucell/Janssen, Vanderbilt University Medical Center, and the John D. and Catherine T. MacArthur Foundation. The Project brings together leading academic research centers, industrial partners, nonprofits and governments to address the primary scientific barriers to developing new vaccines and immunotherapies. The Project has been endorsed by 35 of the world’s leading vaccine scientists.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases. For additional information about the company, please visit http://www.regeneron.com or follow @Regeneron on Twitter.

Regeneron Forward-Looking Statements and Use of Digital Media
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation the Human Vaccines Project discussed in this news release; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; ongoing regulatory obligations and oversight impacting Regeneron’s marketed products, research and clinical programs, and business, including those relating to patient privacy; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2014 and its Form 10-Q for the quarter ended September 30, 2015. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Contact at the Human Vaccines Project:
Ted Schenkelberg, MBA/MPH, Tel. 646.441.0894
E-Mail: tschenkelberg@humanvaccinesproject.org

Media Contact at Regeneron:
Alexandra Bowie, Tel. 914.847.3407
E-Mail: alexandra.bowie@regeneron.com

Read the full story at http://www.prweb.com/releases/2016/02/prweb13208560.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Regeneron to Report Fourth Quarter and Full Year 2015 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2016
2. Trading in Regeneron Common Stock Halted
3. Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments
4. Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
5. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
6. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
7. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
8. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. Regeneron Reports First Quarter 2013 Financial and Operating Results
11. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/13/2018)... ... November 12, 2018 , ... AseptiScope(TM), ... that two large U.S. studies, published last week, confirm pose a significant health ... Infection Control (AJIC) conclude that stethoscopes are often improperly or rarely disinfected. In ...
(Date:11/11/2018)... ... , ... Triple W, an innovator of connected health devices, today announced that ... DFree ®, the first health tech wearable device for incontinence that monitors how full ... The announcement was made during CES Unveiled New York, an invite-only tech event bringing ...
(Date:11/7/2018)... ... November 07, 2018 , ... Diversified Technologies, Inc. ... at AzCATI, the Arizona Center for Algae Technology and Innovation at ASU. Funded by ... and trials for those involved with algal and predator control applications. , Algae ponds ...
(Date:11/5/2018)... (PRWEB) , ... November 05, 2018 , ... ... for access to 2Blades’ Transcription Activator Like (TAL) effector code technology for applications ... commercial uses of the technology in plants. Since its discovery in 2009, the efficacy ...
Breaking Biology Technology:
(Date:11/29/2018)... ... November 29, 2018 , ... ... Biosciences with the intention of acquiring full ownership. The transaction was approved by ... executed on November 14, 2018. “We are extremely pleased to team up with ...
(Date:11/27/2018)... THORNTON CLEVELEYS, U.K. (PRWEB) , ... November 27, ... ... polymer to offer the cryogenics industry a sealing solution with a broader range ... (27-29 November) the No-1 PEEK expert will introduce its new VICTREX CT™ 200 ...
(Date:11/20/2018)... ... November 19, 2018 , ... Cloudponics , maker of the ... today announced a discount of $420 for its industry-leading product during the holiday season. ... in full, with other discount and payment options available on the Cloudponics website ...
Breaking Biology News(10 mins):